Salt Lake City, UT — January 21, 2026 — DiscGenics, Inc., a privately held, late-stage clinical biopharmaceutical company developing regenerative cell-based therapies for degenerative diseases of the spine, previously announced the treatment of the first patient in its U.S. Phase III clinical trial; today, the company is sharing that Nasdaq recognized the milestone by displaying a congratulatory message on the Nasdaq Tower in Times Square.
“Treating the first patient in our U.S. Phase III clinical trial is a major milestone for DiscGenics and a meaningful step forward in our mission,” said Flagg Flanagan, Chairman and Chief Executive Officer of DiscGenics. “We’re proud to see this moment recognized on the Nasdaq Tower in Times Square, but what matters most is what it represents—the dedication of our team and the possibility of making a real difference for patients. As we advance this Phase III study, we remain focused on executing with rigor and urgency, so we can help bring a meaningful new option to the many patients who may benefit.”
This milestone reflects the company’s clinical momentum and operational readiness, supported by DiscGenics’ vertically integrated manufacturing facility and ability to produce cGMP clinical supply to support the program.
About the Phase 3 DGX-A02 Trial
DGX-A02 is a prospective, randomized, double-blind, sham-controlled, multicenter Phase 3 clinical trial designed to evaluate the safety and efficacy of IDCT in subjects with single-level, symptomatic mild-to-moderate lumbar (L3–S1) intervertebral disc degeneration. The trial is expected to enroll approximately 162 subjects and includes a 52-week primary period followed by a 52-week follow-up period (total 104 weeks). The trial is registered at ClinicalTrials.gov (NCT07254806).
About IDCT (Injectable Disc Cell Therapy, Rebonuputemcel)
IDCT is an investigational, single-injection biologic treatment designed to halt the progression of lumbar disc degeneration and regenerate the disc from within. The active component of IDCT is a live, manufactured progenitor cell population derived from donated adult human intervertebral disc tissue, delivered via a viscous carrier. IDCT has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration. IDCT has not been approved by the FDA or any other regulatory authority for any use.
About DiscGenics
DiscGenics is a privately held, late-stage clinical biopharmaceutical company developing allogeneic, cell-based regenerative therapies for musculoskeletal degeneration. Its lead product candidate, IDCT (rebonuputemcel), is a single-injection biologic therapy designed to halt the progression of lumbar disc degeneration and regenerate the disc from the inside out. DiscGenics has developed a proprietary, commercial-scale, in-house allogeneic cell manufacturing process and built a cGMP facility at its Salt Lake City, Utah headquarters.
For more information, visit discgenics.com
This press release contains forward-looking statements, including statements regarding the conduct and progress of DiscGenics’ Phase 3 clinical trial of IDCT (rebonuputemcel), site activation, and the expected enrollment and timing of the study. Actual results may differ materially due to risks and uncertainties inherent in clinical development and regulatory review. DiscGenics undertakes no obligation to update these statements except as required by law.